Replies to post #118976 on Biotech Values

[JJM760]

After reading your response, I have to chuckle at Kirk's view of Palifosfamide as a "rounding error".

Amrn:
$14.50 was where I said I would re-enter when I sold my position on 4/18. So it is kind of stuck in my head. I agree that it may very well have been fairly valued at $17 where I sold out.

Aria:
I know you were a skeptic due to Mrk's lack of pounding the table on Rida after the Succeed results. Are you looking to the follow through data (good or bad) as a potential entry?

Regards, Joe